Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Brain and Behavior Research Fund, and was created with funding from the U.S. National Institute of Mental Health.
Printable version  
SZGene - Gene overview of all published SZ-association studies for SLC6A3    
Back Search Methods Disclaimer Credits
 Gene: SLC6A3  (DAT; DAT1)  Entrez Gene    View on AlzGene   View on PDGene
 Protein: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3  (dopamine transporter)  ProteinLink
 Chromosome: 5   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 22 October 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      SZ Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Alvarez, 2009
Spain CL  2  (detail)  159
(-)
IV--290
(62%)
61.7 + 11
(-)
Negative
Bodeau-Pean, 1995
France CL  1  (detail)  91
(32%)
IIIR24 + 6.2
(-)
42 + 12
(-)
91
(45%)
48 + 11
(-)
Negative
Cordeiro, 2004
Brazil CL  1  (detail)  220
(-)
IV--226
(22%)
-Negative
Daniels, 1995
UK CL  1  (detail)  92
(39%)
IIIR-56
(26-87)
84
(42%)
52
(18-95)
Negative
Hoogendoorn, 2005
Netherlands CL  1  (detail)  208
(-)
IV--288
(-)
-Negative
Joober, 2000
Canada CL  1  (detail)  106
(29%)
IV-39.5 + 8.3
(-)
89
(-)
-Negative
Mas, 2009
Spain CL  14  (detail)  159
(-)
IV--373
(54%)
51.9 + 19
(-)
Negative
Meda, 2009
USA CL  1  (detail)  31
(-)
IV--35
(-)
-Negative
Pal, 2009
Croatia CL  8  (detail)  103
(42%)
10-436 + 106
(23-74)
131
(-)
503 + 75
(30-74)
Positive
Persico, 1997
Italy CL  1  (detail)  147
(37%)
IIIR--84
(-)
-Trend
Prata, 2009b
Overlaps with
Prata, 2009c
CL  1  (detail)  41
(-)
IV--44
(-)
-n.a.
Prata, 2009c
UK CL  1  (detail)  41
(17%)
IV-35.2 + 11.4
(-)
44
(50%)
33.4 + 10.1
(-)
Positive
Saiz, 2009
Spain CL  1  (detail)  288
(40%)
IV-363 + 124
(-)
421
(49%)
406 + 113
(-)
Positive
Szekeres, 2004
Hungary CL  1  (detail)  75
(55%)
IV--45
(62%)
36.4 + 12.8
(-)
Negative
Talkowski, 2008
USA CL  17  (detail)  478
(-)
IV--501
(-)
-Positive
Talkowski, 2008
Overlaps with
Talkowski, 2008
CL  6  (detail)  328
(-)
IV-501
(-)
--n.a.
 Asian
Fujiwara, 1997
Japan CL  1  (detail)  115
(-)
M--26
(-)
-Negative
Huang, 2009
China CL  6  (detail)  352
(38%)
IV27.7 + 11.2
(-)
36.4 + 12.3
(-)
311
(35%)
38 + 10.7
(-)
Positive
Inada, 1996
Japan CL  1  (detail)  118
(54%)
IIIR-59
(22-86)
117
(53%)
46
(20-80)
Negative
Jeong, 2004
Korea CL  4  (detail)  252
(40%)
IV-33.2 + 8.2
(-)
271
(41%)
22.4 + 6.6
(-)
Negative
Li, 1994
China CL  1  (detail)  105
(33%)
U-27.5 + 7.4
(15-51)
98
(36%)
25 + 6.9
(19-50)
Negative
Liu, 2004
Taiwan CL  1  (detail)  79
(6%)
IV23.5 + 8.4
(-)
29.1 + 6.2
(-)
72
(8%)
29.6 + 6.8
(-)
Negative
 Other/Mixed
Galehdari, 2009
Iran CL  1  (detail)  200
(42%)
IV-43.3 + 11.3
(-)
200
(-)
39.4 + 11.1
(-)
Negative
Khodayari, 2004
Iran CL  1  (detail)  100
(0%)
IV-40.9 + 8
(-)
100
(0%)
45 + 5.4
(-)
Positive
Martinez, 2001
USA CL  1  (detail)  28
(-)
IV--31
(-)
-Negative
Semwal, 2002
India CL  1  (detail)  536
(44%)
IV-22.8 + 7
(-)
936
(47%)
32.9 + 12.7
(-)
Negative
Wonodi, 2008
USA CL  1  (detail)  190
(-)
IV--160
(-)
-Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Cordeiro, 2004
Brazil  1  (detail)  4949
(-)
IV--98
(50%)
-Negative
Georgieva, 2002
Bulgaria  1  (detail)  178178
(51%)
IV23.7 + 7.1
(-)
-356
(50%)
59.6 + 9.1
(-)
Negative
Stober, 2006
Germany  4  (detail)  8282
(32%)
U23 + 6.2
(-)
29.8 + 7.3
(-)
164
(50%)
-Positive
Talkowski, 2008
Bulgaria  16  (detail)  659659
(50%)
IV--1318
(50%)
-Positive
Talkowski, 2008
USA  6  (detail)  150150
(50%)
IV--300
(50%)
-Positive
 Other/Mixed
Fanous, 2004
USA  1  (detail)   197
(-)
IIIR--177
(-)
-Negative
Maier, 1996
Germany, Israel  2  (detail)  108-U----Negative
Semwal, 2001
India  1  (detail)  178179
(42%)
IV22.1 + 6.3
(-)
---Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis ->  "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Research Participants
Collaborators
Copyright © 2005-2019 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright